News · Yahoo Finance

Civeo Corporation Q3 2026 Earnings Call Summary

See the full story in the original article.

Read the original on Yahoo Finance ↗

Keywords

earningsbusinesses

Open a keyword to see other news on the same topic.

Related news

Related markets

US stocks →

Latest news

  • In the hunt for $1 trillion of revenue, SpaceX reportedly targets Boost Mobile for a deal

    The article says there has been intense speculation about SpaceX's ambitions in the cellular market, with multiple acquisition targets suggested. Boost Mobile is the latest of these.

    MarketWatch·SpaceXmergers and acquisitionstelecommunications
  • Gold prices today, Monday, November 2, 2026: Gold opens at its lowest point in over a year ahead of midterms

    Gold December futures opened at $3,890 per troy ounce on Monday, down 0.2% from Friday's close, and rose slightly to $3,913.70 by 7:02 a.m. ET. The opening price was the lowest since October 3, 2025, as a sharp equities selloff led investors to sell gold to raise cash, according to Dana Samuelson of American Gold Exchange. He said the gold market was already weak and vulnerable, trading just above its major July support of $3,975, and its break below that level worsened the decline. Compared with a week, a month and a year earlier, the opening price was down 3%, 7.5% and 3.7%, respectively.

    Yahoo Finance·▼ XAU/USD▼ PAXG/USDT▼ XAUT/USDT
  • Marvell Plunges 13% on Lumentum Takeover Rumors: Make Your 3-5 Year Bet Right Now

    Marvell (MRVL) shares fell 14.05% over the past week to $196.40 after reports of a possible takeover of Lumentum (LITE), and Marvell has issued no official statement. Lumentum's market cap is about $76.2 billion versus about $172.2 billion for Marvell, and the article says a deal would be a heavy lift, possibly requiring new stock or debt on top of $4.96 billion in existing debt. Marvell raised its fiscal 2027 revenue outlook to roughly $12 billion and fiscal 2028 to about $18 billion, and the stock trades at 26x forward earnings. Of 46 analysts covering the stock, 8 rate it Strong Buy, 32 Buy, 6 Hold and none Sell, with a consensus target of $340.56 implying 73.4% upside. Risks cited include reliance on a few hyperscalers and a beta of 2.26, and the fiscal third-quarter report, measured against guidance of $3.15 billion revenue and $1.10 non-GAAP EPS, is the next checkpoint.

    Yahoo Finance·MarvellLumentummergers and acquisitions
  • AWS Holds the Scale Crown, Azure Leads the Velocity Charge

    AWS and Azure both posted record quarters but are growing in different ways. AWS revenue reached $45.98 billion, up 39%, its sixth straight quarter of faster growth, with a 38.7% operating margin. Azure grew 48%, daily Copilot users rose over 5x, and CFO Amy Hood forecast 49% to 50% constant-currency Azure growth next quarter. Amazon designs its own Trainium chips and plans to sell them outside AWS in late 2027, while Microsoft Cloud gross margin slipped to 66%. Microsoft generated $18.6 billion of free cash flow, while Amazon's trailing free cash outflow reached $42.4 billion.

    Yahoo Finance·• AMZN▲ MSFTcloud computingearningsAmazon
  • Tech stocks enter November after a brutal October: Is it time to buy the dip?

    According to the article, both stock and bond markets are raising doubts about whether the AI trade can be sustained after a difficult October for tech stocks.

    MarketWatch·• QQQ• SPY
  • Should You Invest $1,000 in BridgeBio Pharma Right Now?

    BridgeBio Pharma (BBIO) focuses on rare genetic diseases and has two approved therapies, Attruby and Nulibry, with Attruby accounting for 71% of third-quarter revenue. The article lists three upcoming FDA milestones: a PDUFA date of Nov. 27 for BBP-418, Feb. 4 for oral infigratinib and May 8 for encaleret. Third-quarter total revenue reached $353.2 million, up 193% year over year, including $253.2 million of U.S. net product revenue for Attruby, while the EPS loss narrowed to $0.42 from $0.95. The company reported more than $1.5 billion in cash, nearly 3 times the year-ago level, after closing a $1 billion preferred equity financing. The article acknowledges risks tied to small patient populations but presents three reasons to consider the stock.

    Yahoo Finance·pharmaceuticalsearningsFDA

All news →

Get the briefing on Telegram or Zalo

Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.